EZH2 and cancer: Further investigation into the EZH2 signaling pathway in the regulation of neuropathic pain would yield novel molecular targets for the development of analgesics and provide a basis for repurposing EZH2 inhibitors for the management of neuropathic pain, given that EZH2 inhibitors have been approved by the FDA [47] and undergone clinical trials [17] for cancer treatment.